Kilitch Drugs (India) Ltd

- The company plans to fund the Khopoli plant expansion primarily through external loans, with bank sanctions already obtained for the funding. - There is no mention of any planned equity fundraising related to this expansion or otherwise. - For non-core assets like land in Bhiwandi, monetization might be considered at the right time, but the current focus remains on pharma operations and the capex projects. - The company aims to sustain growth through internal accruals and bank funding rather than new equity issuance.

- Khopoli Plant Expansion: - Estimated capital expenditure: More than INR 100 crores. - Funding: Mostly through external bank loans; sanctions have been received. - Timeline: Plant construction to take about two years; production expected to start from March 2025 onwards. - Capacity details to be consolidated and shared later. - Ethiopia Plant: - Current operations ramping up after initial struggles. - Plans to increase supply and possibly export within African countries. - Government support with tax benefits: Four years of income tax exemption starting July 2021 till July 2025. - Non-core assets: - Land in Bhiwandi may be monetized at the right opportunity but focus remains on pharma-related capex. - Overall, strategic investments focus on expanding manufacturing capacity to meet growing demand in both domestic and export markets.

- Company expects robust growth in Ethiopia business in FY 2023-24 as government has agreed in principle to provide foreign exchange to support imports, enabling full utilization of Cephalosporin plant capacity. - Overall sales growth of 30% to 35% year-on-year was reported, with export commissions rising in line with sales. - Indian pharmaceutical market projected to see double-digit growth, driven by potential increases in government healthcare spending. - Injectable business expected to grow with plans for increased capacity at Khopoli plant; running multiple shifts planned to meet growing demand. - Exports from the Ethiopian plant to other African countries (Sudan, Uganda, Kenya, Tanzania, Nigeria) anticipated within 1-2 years after product registration and approvals. - Capacity expansions and government contracts are expected to drive increased production volumes and revenues. - Continued focus on contract manufacturing and exploring opportunities to monetize non-core land assets for capital deployment.

- Kilitch Drugs India Limited expects continued robust growth in earnings and profits driven by multiple factors. - Domestic pharma market anticipated to grow at double-digit rates, supported by increased government healthcare spend. - Ethiopian manufacturing unit poised for a robust ramp-up, with government backing and forex allocation improving operational capacity. - EBITDA margins have shown improvement (from 14.8% to 18.8%) and management aims for further margin enhancements in coming quarters. - New Khopoli plant expansion (> INR 100 crores capex) will augment capacity, supporting growth, especially in contract manufacturing. - EPS grew significantly to INR 10.09 in FY23 from INR 6.76, with management optimistic on sustaining this growth trajectory. - Overall, growth will be fueled by expansion in both domestic and export markets, capacity ramp-ups, and operational efficiencies.

- No specific numeric details on the current or expected order book were mentioned in the transcript. - The management expressed confidence in demand growth, citing an 8% to 12% year-on-year growth trend in the pharma market. - The additional capacity at the Khopoli plant was conceptualized anticipating increased demand and possible capacity shortfalls. - While no formal offtake agreements for the new capacity were signed, the company expects existing customers to create demand based on market trends. - In Ethiopia, government tenders have been delayed due to forex issues but are expected to be addressed soon, potentially boosting orders. - The private market currently accounts for Ethiopian sales, with supply to government expected to start after forex support. - Overall, management is optimistic about a robust sales ramp-up with capacity expansions supporting growth.